State Street SPDR S&P Biotech ETF on-chain, compared
No token tracks State Street SPDR S&P Biotech ETF in the catalogues TokenBank follows. It trades on-chain as one perpetual future on Hyperliquid — price exposure through a contract, not ownership. Fees, funding and leverage below.
The perpetual
Not ownership: no dividend, no vote, no claim on the share. Funding is paid or received every hour; positive means longs pay shorts. Leveraged positions are liquidated when margin runs out. Settled in stablecoins on Hyperliquid; each market is run by its own deployer (HIP-3).
- Fee taker / maker
- 0.009 % / 0.003 %
- Funding, 7-day avg
- 16.03 % p.a.
- Funding, latest hour
- −66.09 % p.a.
- Max leverage
- 10×, isolated only
- Collateral
- USDC
- 24h volume
- $13K
- Open interest
- $141K
Fees at the entry tier, before volume and referral discounts; the front end you trade through may add its own fee. Funding annualised from hourly rates, positive = longs pay shorts. Read from the Hyperliquid API, 2026-10-04 05:17 UTC. TokenBank takes no fee and has no referral on these markets.
State Street SPDR S&P Biotech ETF, answered.
Is there a tokenized State Street SPDR S&P Biotech ETF?
+
Not in the issuer catalogues TokenBank tracks. State Street SPDR S&P Biotech ETF trades on-chain only as a perpetual future on Hyperliquid — price exposure through a contract, not a token that represents the share.
What does a State Street SPDR S&P Biotech ETF perp cost to hold?
+
Two things. A trading fee — xyz:XBI 0.009 % taker at the entry tier, before any fee the front end adds. And funding, settled every hour: over the last 7 days xyz:XBI averaged 16.03 % a year. Positive funding means longs pay shorts; it changes every hour.